Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses

Journal of Clinical Oncology

Volumn 21, Issue 8, 2003, Pages 1562-1573

  Smith II, John W ^a   Walker, Edwin B ^a   Fox, Bernard A ^a   Haley, Daniel ^a   Wisner, Ketura P ^a   Doran, Teri ^a   Fisher, Brenda ^a   Justice, Lisa ^a   Wood, William ^a   Vetto, John ^a   Maecker, Holden ^a   Dols, Annemiek ^a   Meijer, Sybren ^a   Hu, Hong Ming ^a   Romero, Pedro ^a   Alvord, W Gregory ^a   Urba, Walter J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYTOKINE; FREUND ADJUVANT; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 209 2M; HLA A2 ANTIGEN; HPV16 E7 PEPTIDE; MELANOMA VACCINE; PEPTIDES AND PROTEINS; TETRAMER; UNCLASSIFIED DRUG; CANCER VACCINE; GAMMA INTERFERON; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; LEUKAPHERESIS; MELANOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADULT; AGED; FEMALE; FLUORESCENCE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PILOT STUDY; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; FREUND'S ADJUVANT; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; LEUKAPHERESIS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PILOT PROJECTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0037842136     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.020     Document Type: Article

References (28)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
2. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
3. Sosman JA, Unger JM, Liu P-Y, et al: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067-2075, 2002
4. Parkhurst MR, Salgaller ML, Southwood S, et al: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539-2548, 1996
5. Salgaller ML, Marincola FM, Cormier JN, et al: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749-4757, 1996
6. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968, 1995
7. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
8. Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836-3847, 2001
9. Altman JD, Moss PA, Goulder PJ, et al: Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96, 1996
10. Garboczi DN, Hung DT, Wiley DC: HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A 89:3429-3433, 1992
11. Molldrem JJ, Lee PP, Wang C, et al: A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59:2675-2681, 1999
12. Hoffmann TK, Donnenberg VS, Friebe-Hoffmann U, et al: Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry 41:321-328, 2000
13. Whelan JA, Dunbar PR, Price DA, et al: Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 163:4342-4348, 1999
14. Romero P, Pittet MJ, Valmori D, et al: Immune monitoring in cancer immunotherapy. Ernst Schering Res Found Workshop 30:75-97, 2000
15. Ogg GS, Jin X, Bonhoeffer S, et al: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106, 1998
16. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 162:1780-1788, 1999
17. He XS, Rehermann B, Lopez-Labrador FX, et al: Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 96:5692-5697, 1999
18. Romero P, Dunbar PR, Valmori D, et al: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641-1650, 1998
19. Ranieri E, Kierstead LS, Zarour H, et al: Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading. Immunol Invest 29:121-125, 2000
20. Lee PP, Yee C, Savage PA, et al: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685, 1999
21. + T cells with soluble HLA-A2/Tax 11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol 162:1765-1771, 1999
22. Keilholz U, Weber J, Finke JH, et al: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97-138, 2002
23. Schuchter L, Schultz DJ, Synnestvedt M, et al: A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 125:369-375, 1996
24. Lee KH, Wang E, Nielsen MB, et al: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292-6300, 1999
25. Meijer SL, Dois A, Hu H-M, et al: gp100 peptide vaccination of HLA-A2+ melanoma patients induces peptide-specific T cells capable of recognizing naturally processed antigen. Proc Am Assoc Cancer Res 43:561, 2002 (abstr 2786)
26. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690-1695, 1999
27. Kirkwood JM, Ibrahim J, Lawson DH, et al: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19:1430-1436, 2001
28. Perez-Diez A, Spiess PJ, Restifo NP, et al: Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 168:338-347, 2002